Healthcare Access

Business

Schneider National Navigates Tough Q4 as Freight Demand Falters, Eyes Supply-Driven Recovery

Schneider National's Q4 2025 earnings fell short of expectations, pressured by a sharp late-year drop in freight demand and severe weather. While acknowledging near-term challenges, executives pointed to early signs of market normalization and detailed strategic cost actions aimed at positioning the carrier for an eventual upcycle.

Jan 30, 2026

Business

UBS Initiates Coverage on Zai Lab with Buy Rating, Touts Global Ambitions Beyond China

Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.

Jan 30, 2026

Business

Macquarie Upgrades NIO to Outperform on Strong Q4 Sales, Battery Service Adoption

Investment bank Macquarie has raised its rating on NIO Inc. (NYSE:NIO) from Neutral to Outperform, citing better-than-expected fourth-quarter delivery figures and the growing success of its battery subscription model. The firm also increased its price target to $6.10.

Jan 30, 2026

Business

Genmab Shares Face Target Cut After EPKINLY Trial Misses Survival Goal, But Analysts Keep Faith

H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.

Jan 30, 2026

Business

Analysts Bullish on BeOne Medicines: Phase 3 Success Fuels $3.8B Revenue Forecast for 2025

Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.

Jan 30, 2026

Business

Goldman Sachs Upgrades BioNTech to Buy, Citing Oncology Pipeline as Key Growth Driver

Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.

Jan 30, 2026

Business

Landlords' Tax Return Deadline Looms: A Guide to Navigating Reliefs and Avoiding Penalties

With key self-assessment deadlines approaching, property investors must navigate a changed landscape of tax reliefs and allowable expenses to minimise their liabilities. Experts urge early preparation to avoid costly surprises.

Jan 30, 2026

World

Exclusive: China Grants Conditional Nod for DeepSeek to Procure Nvidia's H200 AI Chips

Chinese regulators have conditionally approved leading AI startup DeepSeek to purchase Nvidia's advanced H200 artificial intelligence chips, sources tell Reuters, as Beijing navigates competing pressures to advance its tech sector while managing geopolitical tensions.

Jan 30, 2026

Business

Apple Reportedly Shifts 2026 iPhone Strategy: Premium Models Take Priority, Standard Edition Faces Delay

Apple is reportedly planning to prioritize the launch of its three highest-tier iPhone models in 2026, while delaying the rollout of a new standard edition, according to a Nikkei Asia report citing sources familiar with the matter. The move signals a strategic pivot towards the premium segment amid ongoing supply chain considerations.

Jan 30, 2026

Business

AI Bubble Fears Loom Over 2026 Markets, But This S&P 500 ETF Remains a Bedrock Strategy

As trillion-dollar AI infrastructure spending fuels concerns of a market bubble, long-term investors are questioning whether broad index funds like the Vanguard S&P 500 ETF still offer a safe harbor.

Jan 30, 2026

Business

CFTC Chair Charts New Course for Prediction Markets, Vowing Clarity for Polymarket and Kalshi

In a major policy shift, the CFTC under new Chairman Michael Selig is drafting a comprehensive rulebook for event contracts, aiming to bring regulatory certainty to the fast-growing prediction market industry while fostering 'permissionless innovation.'

Jan 30, 2026

Business

Insider Bets Signal Confidence in Select European Growth Stocks Amid Market Uncertainty

As the STOXX Europe 600 stumbles under geopolitical and trade pressures, a focus on companies with significant insider ownership reveals where leadership is putting its own capital on the line. We examine three firms where high insider stakes coincide with robust growth forecasts.

Jan 30, 2026

Business

Nuvation Bio's Ibtrozi Gains Favor on Strong Launch, Truist Raises Target

Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.

Jan 30, 2026

Business

UBS Bets Big on Biotech Turnaround, Initiates Arcellx Coverage with $100 Target

UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.

Jan 30, 2026

Business

TD Cowen Stands By Alphatec (ATEC) With Buy Rating, Sees $20 Target Amid Coverage Shift

Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.

Jan 30, 2026

Business

Mineralys Therapeutics Submits New Drug Application for Hypertension Treatment Lorundrostat, Backed by Strong Clinical Data

Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.

Jan 30, 2026

Business

Analysts Bullish on Cipher Mining as Pivot to AI Infrastructure Gains Momentum

Keefe Bruyette significantly raises its price target for Cipher Mining (CIFR), citing the company's strategic expansion into AI and high-performance computing data centers as a key growth driver.

Jan 30, 2026

Business

Bank of America Bullish on Apellis, Upgrades to 'Buy' on Strong Drug Launch and Kidney Disease Prospects

Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.

Jan 30, 2026

Business

Kyndryl Doubles Down on AI-Driven SAP Modernization in Bid to Redefine Legacy IT Services

The IT infrastructure giant is deepening its SAP partnership with a new Center of Excellence and an AI-powered 'Clean Field' methodology, aiming to automate complex migrations and modernizations for enterprise clients. The strategic push highlights Kyndryl's attempt to pivot from low-margin maintenance work to higher-value AI-enabled transformation services.

Jan 30, 2026

Business

Stryker Caps Record Year with Strong Q4, Bullish on 2026 Despite Market Headwinds

The medical technology giant reports double-digit organic sales growth for the fourth consecutive year, driven by its Mako robotic system and strategic leadership shifts, while navigating tariffs and a shifting competitive landscape.

Jan 30, 2026